(MENAFN- GetNews)


"WHIM Syndrome Pipeline Outlook 2025"DelveInsight's,“WHIM Syndrome – Pipeline Insight, 2025,” report provides comprehensive insights about companies and pipeline drugs in WHIM Syndrome pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

As WHIM Syndrome continues to gain global attention due to its association with serious comorbidities such as diabetes, cardiovascular disorders, and certain cancers, the need for safer and more effective treatment solutions is becoming increasingly urgent. DelveInsight reports that the current WHIM Syndrome pipeline features numerous pharmaceutical and biotech companies developing promising therapeutic candidates. These investigational therapies are advancing across multiple stages of clinical and preclinical development, highlighting strong innovation and a dedicated effort to tackle a critical health concern.

DelveInsight's“WHIM Syndrome Pipeline Insight 2025” report delivers an in-depth and strategic overview of the active research and development landscape. It examines clinical trial progress, novel therapeutic mechanisms, competitive dynamics, and key initiatives from leading players. The report serves as an essential reference for researchers, investors, and healthcare decision-makers seeking comprehensive insights into the evolving WHIM Syndrome therapeutics market and the transformative advancements shaping its future.

Explore the Cutting-Edge Landscape of WHIM Syndrome Drug Development

Key Takeaways from the WHIM Syndrome Pipeline Report

• DelveInsight's WHIM Syndrome pipeline report highlights a dynamic and competitive landscape, with multiple active players advancing novel therapies for the treatment of WHIM Syndrome.

• In April 2024, the U.S. FDA granted approval to mavorixafor (brand name Xolremdi) - marking the first-ever therapy specifically indicated for WHIM Syndrome in patients aged 12 years and older.

• Leading companies such as X4 Pharmaceuticals and others are actively exploring new drug candidates aimed at enhancing treatment outcomes and reshaping the therapeutic landscape. Among the most promising therapies under development is Mavorixafor (X4P-001), along with several other potential candidates progressing through various stages of the pipeline.

WHIM Syndrome Overview:

WHIM Syndrome is a rare primary immunodeficiency disorder in which the immune system fails to function effectively. The term“WHIM” is derived from the main characteristics of the condition: Warts, Hypogammaglobulinemia, Infections, and Myelokathexis. People affected by WHIM Syndrome are highly susceptible to severe bacterial infections and recurrent viral infections, especially those caused by human papillomavirus (HPV), which can result in skin and genital warts and elevate the risk of certain cancers.

A defining feature of the disorder is neutropenia-a significant decrease in neutrophils, the white blood cells crucial for fighting infection. This reduction is due to the abnormal trapping of neutrophils within the bone marrow, a process known as myelokathexis. In most cases, the condition arises from mutations in the CXCR4 gene, usually inherited in an autosomal dominant pattern.

Download the WHIM Syndrome sample report to know in detail about the WHIM Syndrome treatment market

WHIM Syndrome Pipeline Analysis

The WHIM Syndrome pipeline insights report 2025, provides insights into:

• Provides comprehensive insights into key companies developing therapies in the WHIM Syndrome Market.

• Categorizes WHIM Syndrome therapeutic companies by development stage: early, mid, and late-stage.

• Highlights major companies involved in targeted therapy development, including both active and inactive (paused/discontinued) projects.

• Reviews emerging WHIM Syndrome drugs under development based on:

  • Stage of development

  • WHIM Syndrome Route of administration

  • Target receptor

  • Monotherapy vs. combination therapy

  • WHIM Syndrome Mechanism of action

  • Molecular type

• Offers detailed analysis of:

  • Company-to-company and company-academia collaborations

  • WHIM Syndrome Licensing agreements

  • Funding and investment activities supporting future WHIM Syndrome market advancement.

Unlock key insights into emerging WHIM Syndrome therapies and market strategies here:

WHIM Syndrome Emerging Drugs

• Mavorixafor (X4P-001): X4 Pharmaceuticals

X4 Pharmaceuticals is developing Mavorixafor, a first-in-class oral allosteric inhibitor of the CXCR4 receptor, for the treatment of WHIM Syndrome, a rare genetic primary immunodeficiency disorder. WHIM Syndrome results from a gain-of-function mutation in the CXCR4 gene, which produces a shortened and overactive CXCR4 protein. This abnormal activity disrupts normal immune cell trafficking and impairs immune system regulation.

X4 has achieved clinical proof of concept for Mavorixafor in WHIM Syndrome. Results from a completed Phase 2 clinical trial demonstrated significant increases in neutrophil and lymphocyte counts, along with a favorable safety profile. Building on these promising findings, the company has progressed Mavorixafor into a Phase 3 pivotal trial to further evaluate its efficacy and safety in patients with WHIM Syndrome.

WHIM Syndrome Pipeline Therapeutic Assessment

WHIM Syndrome Assessment by Product Type

. Mono

. Combination

. Mono/Combination

WHIM Syndrome By Stage

. Late-stage products (Phase III)

. Mid-stage products (Phase II)

. Early-stage product (Phase I) along with the details of

. Pre-clinical and Discovery stage candidates

. Discontinued & Inactive candidates

WHIM Syndrome Assessment by Route of Administration

. Oral

. Parenteral

. Intravenous

. Subcutaneous

. Topical

WHIM Syndrome Assessment by Molecule Type

. Recombinant fusion proteins

. Small molecule

. Monoclonal antibody

. Peptide

. Polymer

. Gene therapy

Download sample pages to get an in-depth assessment of the emerging WHIM Syndrome therapies and key WHIM Syndrome companies

Table of Contents

1. Report Introduction

2. Executive Summary

3. WHIM Syndrome Current Treatment Patterns

4. WHIM Syndrome - DelveInsight's Analytical Perspective

5. Therapeutic Assessment

6. WHIM Syndrome Late-Stage Products (Phase-III)

7. WHIM Syndrome Mid-Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. WHIM Syndrome Discontinued Products

13. WHIM Syndrome Product Profiles

14. WHIM Syndrome Key Companies

15. WHIM Syndrome Key Products

16. Dormant and Discontinued Products

17. WHIM Syndrome Unmet Needs

18. WHIM Syndrome Future Perspectives

19. WHIM Syndrome Analyst Review

20. Appendix

21. Report Methodology

Request the sample PDF to get detailed insights about the WHIM Syndrome pipeline reports offerings

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

MENAFN15102025003238003268ID1110203039